INMB Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.500

Open

1.470

VWAP

1.46

Vol

170.50K

Mkt Cap

38.55M

Low

1.435

Amount

249.22K

EV/EBITDA(TTM)

--

Total Shares

26.59M

EV

17.19M

EV/OCF(TTM)

--

P/S(TTM)

--

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

Show More

Events Timeline

(ET)

2026-05-15

08:10:00

INmune Bio Publishes Alzheimer's Trial Results

2026-05-14 (ET)

2026-05-14

08:50:00

INmune Bio's XPro Receives FDA Fast Track Designation

2026-04-16 (ET)

2026-04-16

08:10:00

INmune Bio Announces New Preclinical Data for INB03

2026-02-12 (ET)

2026-02-12

07:20:00

INmune Bio Receives FDA Meeting Minutes on XPro1595

2026-02-10 (ET)

2026-02-10

08:10:00

INmune Bio Submits Pre-Submission Package for CORDStrom

2026-01-27 (ET)

2026-01-27

09:30:00

INmune Bio CEO Thanks Investors, Looks Ahead to 2025

2025-12-05 (ET)

2025-12-05

07:10:00

INmune Bio Publishes Overview of Future Applications for MSC Therapies

2025-12-01 (ET)

2025-12-01

08:20:00

INmune Bio Reveals New Neuroimaging Data Showing XPro1595 Slows Alzheimer's Progression

News

Newsfilter

05-19Newsfilter

GT Biopharma Advances NK Cell Immunotherapy with TriKE Candidates

Newsfilter

05-14Newsfilter

INmune Bio Receives FDA Fast Track Designation for XPro™ in Alzheimer's Treatment

seekingalpha

05-07seekingalpha

INmune Bio Reports Q1 2026 Earnings Beat Expectations

Yahoo Finance

03-31Yahoo Finance

INmune Bio Reports $45.9M Loss in 2025 Earnings

seekingalpha

03-30seekingalpha

INmune Bio Reports Disappointing FY Results

Yahoo Finance

03-30Yahoo Finance

INmune Bio Reports Financial Results for FY 2025

2 Analyst Rating

Wall Street analysts forecast INMB stock price to rise

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Lucid Capital

Lucid Capital

Neutral -> Buy

upgrade

$2 -> $9

AI Analysis

2026-03-11

Reason

Lucid Capital

Lucid Capital

Price Target

$2 -> $9

AI Analysis

2026-03-11

upgrade

Neutral -> Buy

Reason

Lucid Capital upgraded INmune Bio to Buy from Neutral with a price target of $9, up from $2. The firm is now factoring into the model the company's CORDStrom therapy for recessive dystrophic epidermolysis bullosa. Lucid cites the expanded scope of value drivers across INmune's pipeline for the upgrade.

Alliance Global Partners

Buy

downgrade

$20 -> $7

2025-07-03

Reason

Alliance Global Partners

Price Target

$20 -> $7

2025-07-03

downgrade

Buy

Reason

Alliance Global Partners lowered the firm's price target on INmune Bio to $7 from $20 and keeps a Buy rating on the shares after the company reported topline Phase 2 data from the MINDful trial of XPro for Alzheimer's disease that "were not what we had hoped for." The firm adjusted its price target to account for the added uncertainly around the future development for XPro and the additional time that will be needed to find a partner and start confirmatory trials, noting that it now values XPro for Alzheimer's at $3 per share.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for INMB

Unlock Now

Valuation Metrics

The current forward P/E ratio for INmune Bio Inc (INMB.O) is 0.00, compared to its 5-year average forward P/E of -4.36. For a more detailed relative valuation and DCF analysis to assess INmune Bio Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-4.36

Current PE

0.00

Overvalued PE

-2.33

Undervalued PE

-6.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

-0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

1171.60

Current PS

5.89

Overvalued PS

3305.85

Undervalued PS

-962.64

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Penny stocks ready to explode

Intellectia · 22 candidates

Region: USPrice: $0.50 - $5.00Volume: >= -100Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceAboveMA200, PriceCrossAboveMA20Week Price Change Pct: >= $0.00Month Price Change Pct: >= $0.00Ema 20: >= 0Ema 60: >= 0Monthly Average Dollar Volume: >= -100Macd: bullish

Ticker

Name

Market Cap$

HCW Biologics Inc

8.22M

Snail Inc

49.44M

CytoMed Therapeutics Ltd

13.73M

Treace Medical Concepts, Inc

172.56M

Jianzhi Education Technology Group Co Ltd

47.23M

Interactive Strength Inc

2.35M

Whales Holding INMB

Trading Trends

People Also Watch

Frequently Asked Questions

What is INmune Bio Inc (INMB) stock price today?

The current price of INMB is 1.45 USD — it has increased 0.69

What is INmune Bio Inc (INMB)'s business?

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

What is the price predicton of INMB Stock?

Wall Street analysts forecast INMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INMB is8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is INmune Bio Inc (INMB)'s revenue for the last quarter?

INmune Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

What is INmune Bio Inc (INMB)'s earnings per share (EPS) for the last quarter?

INmune Bio Inc. EPS for the last quarter amounts to -0.20 USD, decreased -53.49

How many employees does INmune Bio Inc (INMB). have?

INmune Bio Inc (INMB) has 21 emplpoyees as of May 24 2026.

What is INmune Bio Inc (INMB) market cap?

Today INMB has the market capitalization of 38.55M USD.